Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.
How this was made

The 30-second read
Why it matters
The disclosed data address key safety concerns and highlight the unmet disease burden, likely improving market perception of ALXN1840’s commercial potential.
Market read
First public release of pivotal Phase 3 baseline and long‑term safety data, providing fresh material for investors to reassess MNPR’s valuation.
What to watch
Potential competition from other copper‑binding agents and the need for FDA approval timelines.
Background
Monopar Therapeutics (MNPR) is a clinical‑stage biopharma focused on Wilson disease. The company disclosed new Phase 3 baseline disease‑burden metrics and six‑year molybdenum safety data at a major liver conference.
Ticker impact
Monopar Therapeutics presented new Phase 3 baseline disease‑burden data and long‑term molybdenum safety data for its Wilson‑disease drug ALXN1840 at the AASLD Liver Meeting.
likely upward pressure as market prices in the favorable safety profile and disease‑burden insights
First public disclosure of Phase 3 baseline characteristics and six‑year safety data; no prior public release of these specifics.
Market effects
Strengthens the Wilson‑disease therapeutic niche and may raise interest in other rare‑disease biotech pipelines.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech and rare‑disease investors.
Counterpoint
If the data do not translate into regulatory approval or commercial uptake, the hype could fade and the stock may underperform.
Key entities
- companyMonopar Therapeutics Inc.
US‑listed biotech developing ALXN1840 for Wilson disease.
- drugALXN1840 (tiomolibdate choline)
Investigational therapy for Wilson disease.

